• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page


Did Carol in Fleet get axed too?

anonymous

Guest
Seems we are recruiting for a fleet manager on Linkedin and they may explain why no one returns my emails.

We seem to be cutting everything to the bone in an effort to put all behind MariTide. I thought a diversified portfolio was the recommendation?
 








Seems we are recruiting for a fleet manager on Linkedin and they may explain why no one returns my emails.

We seem to be cutting everything to the bone in an effort to put all behind MariTide. I thought a diversified portfolio was the recommendation?
That drug was dead before it arrived. The market already reacted. It’s over